TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19411087

Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/d) for 20 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/d) for 20 weeks + exercise training (3 d/wk from week 10 to week 20)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Active control group (physically active hypercholesterolemic subjects)
Number of subjects: 31
Study: 17260114

Group type: EXPERIMENTAL
Intervention: SR‐PLA70 screws
Number of subjects: 62

Group type: COMPARATOR
Intervention: SR‐PLLA screws
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both SR‐PLA70 and SR‐PLLA screws
Number of subjects: 62
Study: 15078262

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Chloroquine plus sulfadoxine-pyrimethamine (CQ + SP)
Number of subjects: 268
Study: 11430440

Group type: EXPERIMENTAL
Intervention: LIMIRT treatment (840 nm; 3.0 J cm(‐2), pulse frequency 1 kHz)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 9741502

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 8053582

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg) with high-dose midazolam (group 4)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg) with low-dose midazolam (group 2)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (propofol-placebo, group 1)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (midazolam-placebo, group 3)
Number of subjects: 99
Study: 2922831

Group type: EXPERIMENTAL
Intervention: Compression on the extended elbow
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Compression on the flexed elbow
Number of subjects: 24
Study: 31510918

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Regular analgesia (Control)
Number of subjects: 127
Study: 28161119

Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg every 4 weeks
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 26476286

Group type: EXPERIMENTAL
Intervention: Enhanced intervention including in-person support groups, online support groups, peer navigation, and text message reminders.
Number of subjects: 0
Study: 22707232

Group type: EXPERIMENTAL
Intervention: RelyX Unicem with enamel etching (E)
Number of subjects: 31

Group type: COMPARATOR
Intervention: RelyX Unicem without enamel etching (NE)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (E)
Number of subjects: 31

Group type: COMPARATOR
Intervention: RelyX Unicem (NE)
Number of subjects: 31
Study: 21951411

Group type: EXPERIMENTAL
Intervention: In-hospital education plus stroke navigators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19112213

Group type: EXPERIMENTAL
Intervention: Short daily hemodialysis (6 times per week for 1.5 to 2.75 hours)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Long nocturnal hemodialysis (6 times per week for 6 to 8 hours)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Short daily hemodialysis
Number of subjects: 400

Group type: COMPARATOR
Intervention: Long nocturnal hemodialysis
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional in-center hemodialysis
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional home hemodialysis
Number of subjects: 400
Study: 17538472

Group type: EXPERIMENTAL
Intervention: Pneumatic Compression Device 1 (PCD1)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Pneumatic Compression Device 2 (PCD2)
Number of subjects: 65
Study: 16267077

Group type: EXPERIMENTAL
Intervention: Transitional care facility
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 320
Study: 11925995

Group type: EXPERIMENTAL
Intervention: ICT (immunochromatographic card test)
Number of subjects: 242

Group type: COMPARATOR
Intervention: TBF (thick blood film)
Number of subjects: 242

Group type: COMPARATOR
Intervention: NMF (Nuclepore membrane filtration)
Number of subjects: 242
Study: 9793661

Group type: EXPERIMENTAL
Intervention: Subcutaneous and peritoneal bupivacaine (1.5 mg.kg‐1 bupivacaine 0.5%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subcutaneous bupivacaine (1.5 mg.kg‐1 bupivacaine 0.5%)
Number of subjects: 60
Study: 7697953

Group type: EXPERIMENTAL
Intervention: Buspirone (5, 10, and 20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone (doses lower than 20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sumatriptan (50, 100, and 200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sumatriptan (doses unspecified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2515136

Group type: EXPERIMENTAL
Intervention: bepridil (100-400 mg/d)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: propranolol (60-240 mg/d)
Number of subjects: 191

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: bepridil vs propranolol
Number of subjects: 191
Study: 852404

Group type: EXPERIMENTAL
Intervention: BM 15.075 at 450 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BM 15.075 at 600 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: BM 15.075
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no BM 15.075)
Number of subjects: 15
Study: 31771924

Group type: EXPERIMENTAL
Intervention: Safer sex media campaign (Project iMPPACS)
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Nonmedia cities (control)
Number of subjects: 1658
Study: 30955955

Group type: EXPERIMENTAL
Intervention: Antegrade stent delivery
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard repair
Number of subjects: 178
Study: 28549484

Group type: EXPERIMENTAL
Intervention: Guided Internet-based CBT combined with health-related serious gaming elements for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition receiving no intervention
Number of subjects: 60
Study: 24950758

Group type: EXPERIMENTAL
Intervention: 2-micron continuous-wave laser treatment
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional transurethral resection of bladder tumor (TURBT)
Number of subjects: 142
Study: 23852296

Group type: EXPERIMENTAL
Intervention: 25 mg/day mifepristone for 3 months
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 10 mg/day mifepristone for 3 months
Number of subjects: 143
Study: 21358850

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 16
Study: 19595055

Group type: EXPERIMENTAL
Intervention: T2DM patients
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: IGR subjects
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: MAGE
Number of subjects: 83
Study: 16496864

Group type: EXPERIMENTAL
Intervention: Dimensional analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional math method
Number of subjects: 0
Study: 15275754

Group type: EXPERIMENTAL
Intervention: 5.8% hypertonic saline (0.5 ml in each side for each bilateral injection)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 21
Study: 10190658

Group type: EXPERIMENTAL
Intervention: Ropinirole (three times daily for 6 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Digoxin alone (once daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (three times daily for 1 week)
Number of subjects: 10
Study: 7762498

Group type: EXPERIMENTAL
Intervention: Heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 28

Group type: COMPARATOR
Intervention: No drug therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HELP apheresis
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HELP treatments
Number of subjects: 28
Study: 2082485

Group type: EXPERIMENTAL
Intervention: Dipyridamole 100 mg t.i.d. plus warfarin (Study 1)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Slow release capsules of dipyridamole plus warfarin (Study 2)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tablet form dipyridamole plus warfarin (Study 2)
Number of subjects: 250
Study: 371902

Group type: EXPERIMENTAL
Intervention: 150 mg metoprolol once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 300 mg metoprolol once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 150 mg and 300 mg metoprolol
Number of subjects: 32

Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 32
Study: 30706788

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 & 8 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 28061756

Group type: EXPERIMENTAL
Intervention: Experimental group exposed to photos and text of active peers, N = 10
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group exposed to photos and text of inactive peers, N = 11
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 24969380

Group type: EXPERIMENTAL
Intervention: Galantamine (target dose: 24 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Risperidone (target dose: 1.5 mg)
Number of subjects: 100
Study: 22547439

Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 207

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 207
Study: 20183659

Group type: EXPERIMENTAL
Intervention: Guiando a Ninos Activos (GANA)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Standard Parent-Child Interaction Therapy (PCIT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 58
Study: 17442158

Group type: EXPERIMENTAL
Intervention: HS‐LASEK (5% sodium chloride)
Number of subjects: 48

Group type: COMPARATOR
Intervention: A‐LASEK (20% alcohol)
Number of subjects: 48
Study: 15735116

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m(2), days 1 and 4), epirubicin (90 mg/m(2), day 1), and paclitaxel (175 mg/m(2), day 1)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Fluorouracil (500 mg/m(2), day 1), epirubicin (90 mg/m(2), day 1), and cyclophosphamide (500 mg/m(2), day 1)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Gemcitabine, epirubicin, and paclitaxel (GET)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Fluorouracil, epirubicin, and cyclophosphamide (FEC)
Number of subjects: 259
Study: 12139821

Group type: EXPERIMENTAL
Intervention: 5 mg/24 h nitroglycerin patch
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: 10 mg/24 h nitroglycerin patch
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: 15 mg/24 h nitroglycerin patch
Number of subjects: 954

Group type: EXPERIMENTAL
Intervention: All doses of nitroglycerin patches
Number of subjects: 954
Study: 10565799

Group type: EXPERIMENTAL
Intervention: mirtazapine (15-60 mg/day)
Number of subjects: 270

Group type: COMPARATOR
Intervention: citalopram (20-60 mg/day)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: mirtazapine
Number of subjects: 270

Group type: COMPARATOR
Intervention: citalopram
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: mirtazapine and citalopram
Number of subjects: 270
Study: 7881961

Group type: EXPERIMENTAL
Intervention: High-lipid intravenous nutrition (75% non-protein calories supplied as lipid)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous glucose intravenous nutrition (100% non-protein calories supplied as glucose)
Number of subjects: 22
Study: 2404434

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg IM
Number of subjects: 93

Group type: COMPARATOR
Intervention: Cimetidine 300 mg IM
Number of subjects: 93
Study: 6776755

Group type: EXPERIMENTAL
Intervention: Levo-norgestrel (250 microgram daily) and testosterone oenanthate (200 mg monthly)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Levo-norgestrel (500 microgram daily) and testosterone oenanthate (200 mg monthly)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Levo-norgestrel (250 or 500 microgram daily) and testosterone oenanthate (200 mg monthly)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery phase after treatment
Number of subjects: 12
Study: 31532138

Group type: EXPERIMENTAL
Intervention: Otopoint pellet-pressing plus medication (Flunarizine 10 mg twice a day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Medication (Flunarizine 10 mg twice a day)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study: 28513876

Group type: EXPERIMENTAL
Intervention: Standardized education intervention to reduce restraint and agitation
Number of subjects: 0
Study: 26555069

Group type: COMPARATOR
Intervention: cART (efavirenz, tenofovir, and either emtricitabine or lamivudine)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: cART plus integrase inhibitor and CCR5 antagonist (cART+; raltegravir and maraviroc)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined arms (cART and cART+)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Participants (cART and cART+)
Number of subjects: 62
Study: 23414112

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional surgery using an oscillating saw
Number of subjects: 30
Study: 21308888

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for social phobia
Number of subjects: 24
Study: 19438993

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg daily for 4 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (matching placebo for 4 days)
Number of subjects: 6
Study: 17347181

Group type: EXPERIMENTAL
Intervention: Tetracaine 15 mg in 3 ml of glucose 5% (hyperbaric)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tetracaine 15 mg in 3 ml of CSF (isobaric)
Number of subjects: 36
Study: 16797292

Group type: EXPERIMENTAL
Intervention: Strict sodium diet (80 to 100 mmol sodium daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no dietary sodium restriction)
Number of subjects: 32
Study: 15012700

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no sertraline)
Number of subjects: 18
Study: 10802128

Group type: EXPERIMENTAL
Intervention: Citalopram infusion (40 mg per day)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Citalopram tablet (40 mg per day)
Number of subjects: 254
Study: 8605459

Group type: EXPERIMENTAL
Intervention: Double blinding in trials
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Trials with no exclusions after randomisation
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Trials with exclusions
Number of subjects: 110
Study: 1839714

Group type: EXPERIMENTAL
Intervention: Opioid-based anesthetic
Number of subjects: 53

Group type: COMPARATOR
Intervention: Inhaled anesthetic
Number of subjects: 53
Study: 7124302

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between local and general anaesthesia
Number of subjects: 60
Study: 31779508

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SoC) - optimized oral levodopa-carbidopa IR
Number of subjects: 0
Study: 31158254

Group type: EXPERIMENTAL
Intervention: HPV DNA detection and genotyping using Anyplex II HPV28 genotyping test
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Gardasil-9 vaccine genotypes
Number of subjects: 253
Study: 28068906

Group type: EXPERIMENTAL
Intervention: Eat Walk Engage intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 8
Study: 26519056

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trisodium citrate
Number of subjects: 42

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 42
Study: 22562077

Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Number of subjects: 103

Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study: 21209225

Group type: EXPERIMENTAL
Intervention: Meals enriched in monounsaturated fatty acids (MUFAs)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Meals enriched in saturated fatty acids (SFAs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No fat (control)
Number of subjects: 14
Study: 19675489

Group type: EXPERIMENTAL
Intervention: Reduced Training (RT; n = 8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Detraining (DTR; n = 7)
Number of subjects: 15
Study: 17277585

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (including leisure-time physical activity, dietary changes, and weight loss)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Increased total leisure-time physical activity (LTPA)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Favorable dietary changes (using a dietary score)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 481
Study: 15511336

Group type: COMPARATOR
Intervention: Clomiphene citrate (50-150 mg/day for 5 days)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant FSH (daily starting dose 75 IU for up to three consecutive cycles)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant FSH
Number of subjects: 76

Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 76
Study: 11520383

Group type: EXPERIMENTAL
Intervention: Telephone-based anticoagulation service (ACS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (no ACS access)
Number of subjects: 300
Study: 9750705

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 32

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 32
Study: 8174308

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate super‐imposed on cyclical hormonal replacement therapy (HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HRT alone
Number of subjects: 0
Study: 3207544

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg by mouth 8‐14 h and 50 mg i.m. 90 min before surgery
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg i.m. 6‐hourly with a single preinduction dose of sodium citrate 0.3 mol litre‐1 (15 or 30 ml)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sodium citrate 0.3 mol litre‐1 (15 or 30 ml)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sodium citrate 0.3 mol litre‐1 alone
Number of subjects: 110
Study: 31135552

Group type: EXPERIMENTAL
Intervention: Research donation (USD 5 donation to a procedure-specific research program)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Patient donation (USD 5 donation to provide medical supplies to a pediatric orthopaedic patient)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control (no incentive)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Explanation (explanation that response supports quality improvement)
Number of subjects: 3000
Study: 28679524

Group type: EXPERIMENTAL
Intervention: rosuvastatin treatment for 12 months
Number of subjects: 218
Study: 25788006

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate/isotonic saline (MSG/IS) injection in TMJ
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate/isotonic saline (MSG/IS) injection in masseter
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline (IS) injection in masseter
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate/isotonic saline (MSG/IS) injection in masseter and TMJ
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Painful masseter injection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Painful TMJ injection
Number of subjects: 20
Study: 23984393

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21822037

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Computed tomography
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Number of subjects: 156

Group type: COMPARATOR
Intervention: Ultrasonoscopy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Computed tomography and endoscopic ultrasound
Number of subjects: 156
Study: 19105686

Group type: EXPERIMENTAL
Intervention: Risk-tailored information
Number of subjects: 899

Group type: COMPARATOR
Intervention: General information about breast health (Control)
Number of subjects: 899
Study: 17903498

Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural analgesia with 0.2% ropivacaine containing 2 microg/mL fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia with morphine
Number of subjects: 40
Study: 15526700

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous platelet-poor plasma (PPP)
Number of subjects: 0
Study: 12357520

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon (IAB) counterpulsation with inflation volume of 32 cc
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon (IAB) counterpulsation with inflation volume of 40 cc
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon (IAB) counterpulsation
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon (IAB) counterpulsation with larger inflation volumes
Number of subjects: 82
Study: 10531532

Group type: EXPERIMENTAL
Intervention: Carrot juice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 7782353

Group type: EXPERIMENTAL
Intervention: Underarm plastic brace
Number of subjects: 286

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 286

Group type: COMPARATOR
Intervention: Nighttime surface electrical stimulation
Number of subjects: 286